Comparison of 4-versus 5-day Co-Synch plus controlled internal drug release (CIDR) plus timed artificial insemination protocols in dairy heifers

摘要

The objective of this study was to compare the pregnancy rate after timed artificial insemination (P/TAI) in dairy heifers treated with 4- versus 5-day Co-Synch + controlled internal drug release (CIDR) protocols. A total of 120 Holstein heifers were randomly assigned to one of two groups. The heifers received an intravaginal CIDR insert containing 1.38 g of progesterone for 4 days (Monday-Friday 4-day Co-Synch + CIDR; n = 60) or 5 days (5-day Co-Synch + CIDR; n = 60). At the time of CIDR removal, 25 mg of PGF(2 alpha) was injected intramuscularly, and 72 hours after CIDR removal, the heifers received 100 mu g of GnRH intramuscularly and were artificially inseminated. Artificial insemination was performed by an experienced technician, using commercial frozen-thawed semen from a single sire. Pregnancy diagnosis was performed by ultrasonography per rectum 32 days after TAI. Categorical data were analyzed using proc logistic and the chi-square test, whereas continuous variables were analyzed using the t-test of Statistical Analysis Systems. Heifers in the 4-day Co-Synch + CIDR group had an acceptable P/TAI(32) (55.0%, 33 of 60), which was not different (P = 035) from that observed in the 5-day Co-Synch + CIDR group (63.3%, 38 of 60). Progesterone concentration at CIDR insertion or estradiol concentration at TAI did not influence the pregnancy outcomes. Interestingly, estradiol concentration at TAI was greater in the 4-day Co-Synch + CIDR group compared to the 5-day Co-Synch + CIDR group (P 0.01). In conclusion, the Monday to Friday 4-day Co-Synch + CIDR protocol resulted in adequate P/TAI in dairy heifers, which was similar to that of the 5-day Co-Synch + CIDR protocol. This novel protocol might represent a promising hormonal treatment for TAI in dairy heifers, facilitating their reproductive management routine, while maintaining an adequate fertility. (C) 2015 Elsevier Inc. All rights reserved.